Atlas Trials

A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide

Clinical trial NCT01977651 · COMPLETED

Trial details

NCT number
NCT01977651
Sponsor
Astellas Pharma Global Development, Inc.
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Start date
2013-09-25
Primary completion
2016-02-01
Enrollment
424

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.